Support Line: 0300 373 8500
This is an early stage study to better understand a new type of drug.
The drug is a BTK targeted protein degrader, meaning it targets a type of protein called BTK and breaks it down. This protein usually helps cancer cells stay alive, so by breaking the protein down, the drug can either kill the cancer cells or stop them from multiplying.
The trial is focussing on the dosing of the drug and is split into two phases to help researchers understand which doses are most effective.
• Confirmed diagnosis of WM
• Patients may be eligible if they have been treated with BTK inhibitor previously
